Abstract: The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-K?).
Type:
Grant
Filed:
February 9, 2010
Date of Patent:
September 25, 2012
Assignee:
Pfizer Inc
Inventors:
Hengmiao Cheng, Dilip Bhumralkar, Klaus Ruprecht Dress, Jacqui Elizabeth Hoffman, Mary Catherine Johnson, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Michael Bruno Plewe, Khanh Tuan Tran
Abstract: The invention relates to thienopyrimidine and pyrazolopyrimidine compounds of the Formulas (Ia) and (IIa), or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein compositions comprising the compounds, and methods for making and using the compounds.
Type:
Grant
Filed:
October 15, 2008
Date of Patent:
March 6, 2012
Assignee:
Wyeth LLC
Inventors:
Arie Zask, Joshua Aaron Kaplan, Jeroen Cunera Verheijen, Kevin J. Curran, David James Richard, Semiramis Ayral-Kaloustian
Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
Type:
Grant
Filed:
May 22, 2009
Date of Patent:
October 18, 2011
Assignee:
Wyeth LLC
Inventors:
Aranapakam Mudumbai Venkatesan, Zecheng Chen, Christoph Martin Dehnhardt, Osvaldo dos Santos, Efren Guillermo Delos Santos, Arie Zask, Jeroen Cunera Verheijen, Joshua Aaron Kaplan, David James Richard, Semiramis Ayral-Kaloustian, Tarek Suhayl Mansour, Ariamala Gopalsamy, Kevin Joseph Curran, Mengxiao Shi
Abstract: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
Type:
Grant
Filed:
October 15, 2008
Date of Patent:
September 20, 2011
Assignee:
Wyeth LLC
Inventors:
Qinghong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi
Abstract: Compounds of the formula: wherein: n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R1 is 2,4-diCl, 5-OMe; 2,4-diCl; 3,4,5-tri-OMe; 2-Cl, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCl, 5-OEt; R2 is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
June 16, 2008
Date of Patent:
April 5, 2011
Assignee:
Wyeth LLC
Inventors:
Frank Boschelli, Jennifer M. Golas, Kim T. Arndt
Abstract: This invention relates to methods for treating or inhibiting cancers in a mammal in need thereof, which comprises administering an effective amount of a 6-Aryl-7-halo-imidazo[1,2 -a]pyrimidine compound of the formula: or pharmaceutically acceptable salts thereof.
Abstract: The present invention relates to compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are defined herein.
Type:
Grant
Filed:
October 13, 2005
Date of Patent:
September 21, 2010
Assignee:
Wyeth LLC
Inventors:
Fuk-Wah Sum, Dennis William Powell, Yixian Zhang, Lijing Chen, Scott Lee Kincaid, Lee Dalton Jennings, Yongbo Hu, Adam Matthew Gilbert, Matthew Gregory Bursavich
Abstract: This invention provides a compound of Formula 1 where Ar, X, R1, R2, R3, and R4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.
Type:
Grant
Filed:
September 23, 2008
Date of Patent:
August 3, 2010
Assignee:
Wyeth
Inventors:
Dan Maarten Berger, Dennis William Powell, Biqi Wu
Abstract: This invention is directed to a crystalline 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2? angles (°) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109° C. to about 115° C.
Type:
Grant
Filed:
June 29, 2006
Date of Patent:
August 3, 2010
Assignee:
Wyeth LLC
Inventors:
Marc Sadler Tesconi, Gregg Feigelson, Henry Strong, Hong Wen
Abstract: The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound alone or in combination with an effective amount of an EGF receptor kinase inhibitor.
Abstract: This invention provides a method of treating solid tumors which comprises administering an effective amount of a combination of (1) a bioresponse modifier and (2) a chemotherapeutic agent. This invention also provides a method of potentiating the effects of a chemotherapeutic regimen in a mammal in need of treatment with such regimen which comprises administering a bioresponse modifier in addition to a chemotherapeutic regimen.
Type:
Grant
Filed:
September 12, 2000
Date of Patent:
December 16, 2008
Assignee:
Wyeth
Inventors:
James J. Gibbons, Jr., Gary Dukart, Judy Lucas, Lisa A. Speicher
Abstract: This invention provides a compound of Formula 1 where Ar, X, R1, R2, R3, and R4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.
Type:
Grant
Filed:
February 16, 2005
Date of Patent:
November 11, 2008
Assignee:
Wyeth
Inventors:
Dan Maarten Berger, Dennis William Powell, Biqi Wu
Abstract: This invention relates to a method for the regioselective synthesis of 4,6,7,8-substituted benzo[g]quinoline-3-carbonitriles and 4,6,7,8-substituted benzo[g]quinazolines as well as intermediates thereof. The compounds derived from this invention are useful for the treatment of a variety of diseases that are a result of deregulation of these PTK's, and more specifically, are anti-cancer agents and are useful for the treatment of cancer in mammals. In addition, the compounds derived from this invention are useful for the treatment of polycystic kidney disease in mammals.
Type:
Grant
Filed:
December 11, 2001
Date of Patent:
April 29, 2008
Assignee:
Wyeth
Inventors:
Dan Maarten Berger, Gary Harold Birnberg, Yanong Wang
Abstract: The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R1, R2, R3, R4, R5 and R6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilizing them
Type:
Grant
Filed:
March 21, 2003
Date of Patent:
October 23, 2007
Inventors:
Rebecca Elizabeth Brown, Victoria Alexandra Doughty, Gregory John Hollingworth, A. Brian Jones, Matthew John Lindon, Christopher Richard Moyes, Lauren Rogers
Abstract: Tetrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
Type:
Grant
Filed:
October 1, 2002
Date of Patent:
August 7, 2007
Assignee:
Merck & Co., Inc.
Inventors:
Nicholas D. P. Cosford, Chixu Chen, Thomas S. Reger, Jeffrey R. Roppe, Nicholas D. Smith
Abstract: The present invention is directed to compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, W, X, and n are defined herein, which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.
Type:
Grant
Filed:
October 24, 2003
Date of Patent:
July 24, 2007
Assignee:
Merck & Co., Inc.
Inventors:
Gabor Butora, Alexander Pasternak, Lihu Yang, Changyou Zhou
Abstract: The present invention is directed to compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Type:
Grant
Filed:
June 14, 2005
Date of Patent:
June 26, 2007
Assignee:
Merck & Co., Inc.
Inventors:
Christopher S. Burgey, Zhengwu J. Deng, Diem N. Nguyen, Daniel V. Paone, Anthony W. Shaw, Theresa M. Williams